Esperion Therapeutics, Inc. (ESPR) Can’t Burn Your Long Portfolio. Just Reaches 52-Week High

January 14, 2018 - By Vivian Park

Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It is positive, as 11 investors sold Esperion Therapeutics, Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported.
First Trust Advisors Limited Partnership holds 9,205 shares or 0% of its portfolio. Voloridge Inv Management Lc reported 0.1% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Trexquant Ltd Partnership holds 16,591 shares. 22,425 are owned by Rothschild Asset Management Inc. Partner Invest Management Ltd Partnership holds 0.43% or 9,119 shares in its portfolio. Great West Life Assurance Company Can owns 1,300 shares. Parallax Volatility Advisers Limited Partnership, a California-based fund reported 10,469 shares. Hall Laurie J Trustee reported 280 shares or 0.01% of all its holdings. Credit Suisse Ag holds 1.06 million shares or 0.05% of its portfolio. Morgan Stanley holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 33,212 shares. Sg Americas Lc invested in 3,423 shares. Eam Investors Ltd accumulated 0.62% or 92,899 shares. 174,097 are owned by Invesco Ltd. Quantitative Investment Lc stated it has 0.07% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 15,640 were accumulated by Proshare Advsrs Ltd Llc.

The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) hit a new 52-week high and has $79.12 target or 8.00 % above today’s $73.26 share price. The 7 months bullish chart indicates low risk for the $1.92 billion company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $79.12 price target is reached, the company will be worth $153.52M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 4.79% or $3.35 during the last trading session, reaching $73.26. About 917,587 shares traded or 68.34% up from the average. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since January 14, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 EPS, down 39.53 % or $0.51 from last year’s $-1.29 per share. After $-1.86 actual EPS reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.23 % EPS growth.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 12 have Buy rating, 0 Sell and 6 Hold. Therefore 67% are positive. Esperion Therapeutics has $130.0 highest and $10 lowest target. $47.06’s average target is -35.76% below currents $73.26 stock price. Esperion Therapeutics had 50 analyst reports since July 28, 2015 according to SRatingsIntel. Northland Capital maintained the stock with “Buy” rating in Tuesday, October 3 report. The firm has “Buy” rating by Citigroup given on Tuesday, February 28. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Wednesday, November 22 by Northland Capital. The firm has “Buy” rating by Deutsche Bank given on Wednesday, August 9. Credit Suisse upgraded Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Monday, March 20 to “Neutral” rating. The firm earned “Strong Buy” rating on Wednesday, August 19 by Needham. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. Barclays Capital downgraded it to “Equal-Weight” rating and $13 target in Wednesday, June 29 report. The firm earned “Buy” rating on Friday, January 5 by Bank of America. The firm has “Buy” rating by Needham given on Thursday, December 14.

More news for Esperion Therapeutics, Inc. (NASDAQ:ESPR) were recently published by: Fool.com, which released: “Why Esperion Therapeutics Shares Skyrocketed 425.9% in 2017” on January 06, 2018. Valuewalk.com‘s article titled: “Activist Investor Report for December 29, 2017 – Esperion Therapeutics Inc …” and published on January 02, 2018 is yet another important article.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.92 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.